Molecular targets of gambogic acid in cancer: recent trends and advancements

Tumor Biology

Volumn 37, Issue 10, 2016, Pages 12915-12925

  Kashyap, Dharambir ^a   Mondal, Rajkumar ^b   Tuli, Hardeep Singh ^b   Kumar, Gaurav ^c   Sharma, Anil K ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Anti inflammatory; Antiangiogenesis; Antimetastasis; Apoptosis; Autophagy; Gambogic acid; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; GAMBOGIC ACID; NATURAL PRODUCT; TELOMERASE INHIBITOR; XANTHONE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOPHAGY; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; BIOSAFETY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; DEGENERATIVE DISEASE; DRUG ANTAGONISM; GARCINIA HANBURYI; HUMAN; MALIGNANT NEOPLASM; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; TREE; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; XANTHONES;

EID: 84979582182     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5194-8     Document Type: Review

References (115)

1. Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin. 3 Biotech. Springer; 2013;4:1–12.
2. Sharma A, Tuli HS, Sandhu SS Optimization of extraction conditions and antimicrobial potential of a bioactive metabolite, Cordycepin from Cordyceps militaris 3936. 2014
3. Tuli HS, Chaudhary P, Beniwal V, Sharma AK. Microbial pigments as natural color sources: current trends and future perspectives. J Food Sci Technol. 2015;52:4669–78.
4. Hunter P. Harnessing Nature’s wisdom. Turning to nature for inspiration and avoiding her follies. EMBO Rep. 2008;9:838–40.
5. Prasad S, Pandey MK, Yadav VR, Aggarwal BB. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila). 2011;4:1084–94.
6. HY Gu, QL Guo QY. Gambogic acid inducing apoptosis in human hepatoma SMMC-7721 cells with p53 and Bax up-regulated. Scienceopen.com. 2005;
7. Zhang H-Z, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem. 2004;12:309–17.
8. Wu Z-Q, Guo Q-L, You Q-D, Zhao L, Gu H-Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004;27:1769–1774.
9. Guo Q-L, Lin S-S, You Q-D, H-Y G, Yu J, Zhao L, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 2006;78:1238–45.
10. Liu W, Guo Q-L, You Q-D, Zhao L, H-Y G, Yuan S-T. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol. 2005;11:3655–9.
11. Gu H, Rao S, Zhao J, Wang J, Mu R, Rong J, et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol. 2009;135:1777–82.
12. Xu X, Liu Y, Wang L, He J, Zhang H, Chen X, et al. Gambogic acid induces apoptosis by regulating the expression of Bax and bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. Int J Dermatol. 2009;48:186–92.
13. Gu H, You Q, Liu W, Yang Y, Zhao L, Qi Q, et al. Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H22 transplanted mice. Int Immunopharmacol. 2008;8:1493–502.
14. Park M-S, Kim N-H, Kang C-W, C-W O, Kim G-D. Antimetastatic effects of gambogic acid are mediated via the actin cytoskeleton and NF-κB pathways in SK-HEP1 cells. Drug Dev Res. 2015;76:132–42.
15. Yi T, Yi Z, Cho S-G, Luo J, Pandey MK, Aggarwal BB, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008;68:1843–50.
16. Wang X, Chen W. Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anti Cancer Agents Med Chem. 2012;12:994–1000.
17. Fang L, Chen B, Liu S, Wang R, Hu S, Xia G, et al. Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/bad pathway of LOVO cells. Int J Nanomedicine. 2012;7:4109–18.
18. Liu N, Huang H, Xu L, Hua X, Li X, Liu S, et al. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo. Toxicol Lett. 2014;224:333–40.
19. Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008;262:214–22.
20. Ren Y, Yuan C, Chai H, Ding Y, Li X-C, Ferreira D, et al. Absolute configuration of (−)-gambogic acid, an antitumor agent. J Nat Prod. 2011;74:460–3.
21. Wang J, Zhao L, Hu Y, Guo Q, Zhang L, Wang X, et al. Studies on chemical structure modification and biology of a natural product, gambogic acid (I): synthesis and biological evaluation of oxidized analogues of gambogic acid. Eur J Med Chem. 2009;44:2611–20.
22. Nicolaou KC, Sasmal PK, Xu H, Namoto K, Ritzén A. Total synthesis of 1-O-methyllateriflorone. Angew. Chem. Int. Ed. Engl. 2003;42:4225–9.
23. Nicolaou KC, Sasmal PK, Xu H Biomimetically inspired total synthesis and structure activity relationships of 1-O-methyllateriflorone. 6 pi electrocyclizations in organic synthesis. J Am Chem Soc 2004;126:5493–5501.
24. Nicolaou KC, Xu H, Wartmann M. Biomimetic total synthesis of gambogin and rate acceleration of pericyclic reactions in aqueous media. Angew Chem Int Ed Engl. 2005;44:756–61.
25. Douglas R. Green SJ. Means to an end: apoptosis and other cell death mechanisms [Internet]. cold spring Harb. Lab. Press. 2011 [cited 2016 Mar 9]. p. ISBN 978–0 – 879698–87 – 4. Available from: http://www.cshlpress.org/default.tpl?cart=145750066015146367&fromlink=T&linkaction=full&linksortby=oop_title&--eqSKUdatarq=884
26. Tuli HS, KUMAR G, Sandhu SS, Sharma AK, Kashyap D. Apoptotic effect of cordycepin on A549 human lung cancer cell line. Turkish J. Biol. 2015. p. 306.
27. Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther. 2008;7:3298–305.
28. Rong J-J, Hu R, Qi Q, H-Y G, Zhao Q, Wang J, et al. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 2009;284:102–12.
29. Wang Y, Chen Y, Chen Z, Ke W-J, Q-L W, He J. [Mechanism of gambogic acid-induced apoptosis in Raji cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:88–91.
30. Li R, Chen Y, Zeng L-L, Shu W-X, Zhao F, Wen L, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology. 2009;262:98–105.
31. Zhong N, Jiang D, Zheng S-Y. Anticancer effect of gambogic acid in gastric cancer line SGC-7901. 2010 4th Int. Conf. Bioinforma. Biomed. Eng IEEE; 2010. p. 1–6.
32. SHI Xian-ping, LAN Xiao-ying, CHEN Xin, WANG Wen-wen, WEN Chuang-yu, HUANG Mei-jin, LIU Huan-liang. Effect of gambogic acid on proliferation and apoptosis of human diffuse large B-cell lymphoma cell line OCI-LY-1--《Chinese Journal of Pathophysiology》2013年05期 [Internet]. 《Chinese J. Pathophysiol. [cited 2016 Mar 8]. p. No.B2012159. Available from: http://en.cnki.com.cn/Article_en/CJFDTotal-ZBLS201305008.htm
33. Yong-gong Y, Qi-guo Z, Jian O, Cui-ping L, Jun-hao C. Effect of gambogic acid on the apoptosis of multiple myeloma U266 cell line and its mechanism. Chinese J. Clin. p. 996–1001.
34. M. Rajasekaran, Prather LP Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity [Internet]. FASEB J. 2009 [cited 2016 Mar 9]. Available from: https://www.google.co.in/?gfe_rd=cr&ei=4LHfVs_5NvCK8Qfb0ZnACQ&gws_rd=ssl#q=Gambogic+acid+binds+to+human+CB2+receptors+and+exhibits+potential+partial+agonist+activity
35. Nie F, Zhang X, Qi Q, Yang L, Yang Y, Liu W, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology. 2009;260:60–7.
36. Li C, Qi Q, Lu N, Dai Q, Li F, Wang X, et al. Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2012;90:718–30.
37. TANG D, LV L, ZENG F, HE J, JIANG G, WANG Z. Gambogic acid inhibits cell proliferation and induces apoptosis of human prostate cancer PC-3 cells in vitro. TUMOR. p. 688–92.
38. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007;110:3517–25.
39. Kim D, Lee T, Kim E, Kang JH, Kim KG, Kim J. Gambogic acid induced apoptosis through activation of caspase-dependent pathway in aortic smooth muscle cells. 2013;26.
40. Zhu X, Zhang H, Lin Y, Chen P, Min J, Wang Z, et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 2009;21:666–72.
41. Huang G-M, Sun Y, Ge X, Wan X, Li C-B. Gambogic acid induces apoptosis and inhibits colorectal tumor growth via mitochondrial pathways. World J Gastroenterol. 2015;21:6194–205.
42. Cui G, Shu W, Wu Q, Chen Y. Effect of gambogic acid on the regulation of hERG channel in K562 cells in vitro. J Huazhong Univ Sci Technolog Med Sci. 2009;29:540–5.
43. Wang X, Chen Y, Han Q, Chan C, Wang H, Liu Z, et al. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics. 2009;9:242–53.
44. Chen J, H-Y G, Lu N, Yang Y, Liu W, Qi Q, et al. Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci. 2008;83:103–9.
45. Rong J-J, Hu R, Song X-M, Ha J, Lu N, Qi Q, et al. Gambogic acid triggers DNA damage signaling that induces p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway. Cancer Lett. 2010;296:55–64.
46. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100:1523–9.
47. Prashanth K Rivathi B. Potential Hsp90 inhibitors: a novel target for cancer therapy. Chemother. Open Access. 2015;04:3–5.
48. Zhang L, Yi Y, Chen J, Sun Y, Guo Q, Zheng Z, et al. Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells. Biochem Biophys Res Commun. 2010;403:282–7.
49. Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BSJ, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod. 2011;74:1085–92.
50. Felth J, Lesiak-Mieczkowska K, D’Arcy P, Haglund C, Gullbo J, Larsson R, et al. Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system. Investig New Drugs. 2013;31:587–98.
51. Pandey MK, Kale VP, Song C, Sung S, Sharma AK, Talamo G, et al. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp Hematol. 2014;42:883–96.
52. Li D, Yang H, Li R, Wang Y, Wang W, Li D, et al. Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation. Oncol Lett. 2015;10:2802–6.
53. Chen J, Zhou M, Zhang Q, Xu J, Ouyang J. Anticancer effect and apoptosis induction of gambogic acid in human leukemia cell line K562 in vitro. Med Sci Monit. 2015;21:1604–10.
54. Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nat Rev Mol Cell Biol. 2015;16:461–72.
55. Noda NN, Inagaki F. Mechanisms of autophagy. Annu Rev Biophys Annual Reviews. 2015;44:101–22.
56. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221:3–12.
57. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961–7.
58. Poillet-Perez L, Despouy G, Delage-Mourroux R, Boyer-Guittaut M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol. 2015;4:184–92.
59. Mei W, Dong C, Hui C, Bin L, Fenggen Y, Jingjing S, et al. Gambogenic acid kills lung cancer cells through aberrant autophagy. PLoS One Public Library of Science. 2014;9:e83604.
60. Yang Y, Sun X, Yang Y, Yang X, Zhu H, Dai S, et al. Gambogic acid enhances the radiosensitivity of human esophageal cancer cells by inducing reactive oxygen species via targeting Akt/mTOR pathway. Tumour Biol. 2015.
61. Yang J, Zhou Y, Cheng X, Fan Y, He S, Li S, et al. Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells. Sci Rep Nature Publishing Group. 2015;5:7697.
62. Luo G-X, Cai J, Lin J-Z, Luo W-S, Luo H-S, Jiang Y-Y, et al. Autophagy inhibition promotes gambogic acid-induced suppression of growth and apoptosis in glioblastoma cells. Asian Pac J Cancer Prev. 2012;13:6211–6.
63. Ishaq M, Khan MA, Sharma K, Sharma G, Dutta RK, Majumdar S. Gambogic acid induced oxidative stress dependent caspase activation regulates both apoptosis and autophagy by targeting various key molecules (NF-κB, Beclin-1, p62 and NBR1) in human bladder cancer cells. Biochim Biophys Acta. 2014;1840:3374–84.
64. Zhang H, Lei Y, Yuan P, Li L, Luo C, Gao R, et al. ROS-mediated autophagy induced by dysregulation of lipid metabolism plays a protective role in colorectal cancer cells treated with gambogic acid. PLoS One. Public Library of Science2014;9:e96418.
65. Chen J, Zhou M, Zhang Q, Xu J, Ouyang J. Gambogic acid induces death of K562 cells through autophagy and apoptosis mechanisms. Leuk Lymphoma. 2015;56:2953–8.
66. Maida Y, Yasukawa M, Okamoto N, Ohka S, Kinoshita K, Totoki Y, et al. Involvement of telomerase reverse transcriptase in heterochromatin maintenance. Mol Cell Biol. 2014;34:1576–93.
67. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science (80). 2015;347:1006–10.
68. Killedar A, Stutz MD, Sobinoff AP, Tomlinson CG, Bryan TM, Beesley J, et al. A common cancer risk-associated allele in the hTERT locus encodes a dominant negative inhibitor of telomerase. PLoS Genet. 2015;11:e1005286.
69. Maida Y, Masutomi K. Telomerase reverse transcriptase moonlights: therapeutic targets beyond telomerase. Cancer Sci. 2015;106:1486–92.
70. Yu J, Guo Q-L, You Q-D, Lin S-S, Li Z, H-Y G, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother Pharmacol. 2006;58:434–43.
71. Guo Q-L, You Q-D, Z-Q W, Yuan S-T, Zhao L. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin. 2004;25:769–74.
72. Zhao Q, Yang Y, Yu J, You Q-D, Zeng S, H-Y G, et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Lett. 2008;262:223–31.
73. Tuli HS, Sharma AK, Sandhu SS, Kashyap D. Cordycepin: a bioactive metabolite with therapeutic potential. Life Sci. 2013;93:863–9.
74. Tuli HS, Kashyap D, Bedi SK, Kumar P, Kumar G, Sandhu SS. Molecular aspects of metal oxide nanoparticle (MO-NPs) mediated pharmacological effects. Life Sci. 2015;143:71–9.
75. Kumar G, Tuli HS, Mittal S, Shandilya JK, Tiwari A, Sandhu SS. Isothiocyanates: a class of bioactive metabolites with chemopreventive potential. Tumour Biol. 2015;36:4005–16.
76. Srirupa Mukhopadhyay, Parth Malik, Sunil Kumar Arora TKM. Molecular mechanisms of tumor cell resistance to chemotherapy. Bonavida B, editor. New York, NY: Springer New York; 2013.
77. Lü L, Tang D, Wang L, Huang L, Jiang G, Xiao X, et al. Gambogic acid inhibits TNF-α-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-κB signaling pathways. Acta Pharmacol Sin. 2012;33:531–41.
78. Qi Q, Lu N, Li C, Zhao J, Liu W, You Q, et al. Involvement of RECK in gambogic acid induced anti-invasive effect in A549 human lung carcinoma cells. Mol Carcinog. 2015;54(Suppl 1):E13–25.
79. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer. Nature Publishing Group; 2007;7:554–562.
80. Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, et al. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl). 2008;86:1367–77.
81. Qi Q, Lu N, Wang X, Gu H, Yang Y, Liu W, et al. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 2008;86:386–95.
82. Tuli HS, Sandhu SS, Sharma AK, Gandhi P. Anti-angiogenic activity of the extracted fermentation broth of an entomopathogenic fungus, Cordyceps militaris 3936. Int. J. Pharm. Pharm. Sci. 2014.
83. Lu N, Yang Y, You Q-D, Ling Y, Gao Y, H-Y G, et al. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett. 2007;258:80–9.
84. Kumar G, Mittal S, Sak K, Tuli HS. Molecular mechanisms underlying chemopreventive potential of curcumin: current challenges and future perspectives. Life Sci. 2016;148:313–28.
85. Qiang L, Yang Y, You Q-D, Ma Y-J, Yang L, Nie F-F, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol. 2008;75:1083–92.
86. Lu N, Hui H, Yang H, Zhao K, Chen Y, You Q-D, et al. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci. 2013;49:220–6.
87. Wang F, Zhang W, Guo L, Bao W, Jin N, Liu R, et al. Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci. 2014;105:1063–70.
88. Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): a metabolite with promising therapeutic potential. Life Sci. 2016;146:201–13.
89. Zhao C, Liu S, Yang C, Li X, Huang H, Liu N, et al. Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway. Am J Cardiovasc Dis. 2013;3:135–45.
90. Geng J, Xiao S, Zheng Z, Song S, Zhang L. Gambogic acid protects from endotoxin shock by suppressing pro-inflammatory factors in vivo and in vitro. Inflamm Res. 2013;62:165–72.
91. Wen J, Pei H, Wang X, Xie C, Li S, Huang L, et al. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation. J Dermatol Sci. 2014;74:242–50.
92. Cascão R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, Gupta V, et al. Potent anti-inflammatory and antiproliferative effects of gambogic acid in a rat model of antigen-induced arthritis. Mediat Inflamm. 2014;2014:195327.
93. Lee JY, Lee BH, Lee JY. Gambogic acid disrupts toll-like Receptor4 activation by blocking lipopolysaccharides binding to myeloid differentiation factor 2. Toxicol Res. 2015;31:11–6.
94. Liu N, Huang H, Liu S, Li X, Yang C, Dou QP, et al. Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation. Toxicol in Vitro. 2014;28:419–25.
95. Ortiz-Sánchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 2009;23:59–70.
96. Huang H, Chen D, Li S, Li X, Liu N, Lu X, et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011;301:221–8.
97. Wang C, Zhang H, Chen B, Yin H, Wang W. Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles. Int J Nanomedicine. 2011;6:1929–35.
98. Zou Z, Xie L, Wei J, Yu L, Qian X, Chen J, et al. Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complement Altern Med. 2012;12:58.
99. Jiang X-L, Zhang Y, Luo C-L, Wu X-H. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13:6463–8.
100. ZOU Zheng-yun, YU Li-xia, CHEN Jun-hao1, WANG Ting-ting LB. The natural interaction between gambogic acid and oxaliplatin and its probably mechanism--《Acta Universitatis Medicinalis Nanjing(Natural Science)》2009年06期 [Internet]. 《Acta Univ. Med. NanjingNatural Sci. 2009 [cited 2016 Mar 8]. p. (ZKX05015). Available from: http://en.cnki.com.cn/Article_en/CJFDTotal-NJYK200906011.htm
101. Chen B, Li J, Wang X. Gambogic acid combined with CdTe QDs for leukemia cancer cells inhibition and their bio-safety for rat brain. Blood American Society of Hematology. 2013;122:5028.
102. Wang X, Deng R, Lu Y, Xu Q, Yan M, Ye D, et al. Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation. Basic Clin. Pharmacol. Toxicol. 2013;112:25–33.
103. Wang L-H, Yang J-Y, Yang S-N, Li Y, Ping G-F, Hou Y, et al. Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer. Curr Cancer Drug Targets. 2014;14:91–103.
104. Wang L-H, Li Y, Yang S-N, Wang F-Y, Hou Y, Cui W, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling. Br J Cancer. 2014;110:341–52.
105. Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, et al. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res. 2014;20:151–63.
106. Wang J, Yuan Z. Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis. Cell Biochem Biophys. 2013;67:199–206.
107. Tuli HS, Kashyap D, Sharma AK, Sandhu SS. Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci. 2015;135:147–57.
108. Guo Q, Qi Q, You Q, Gu H, Zhao L, Wu Z. Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 2006;99:178–84.
109. Qi Q, You Q, Gu H, Zhao L, Liu W, Lu N, et al. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol. 2008;117:433–8.
110. Zhao L, Zhen C, Wu Z, Hu R, Zhou C, Guo Q. General pharmacological properties, developmental toxicity, and analgesic activity of gambogic acid, a novel natural anticancer agent. Drug Chem Toxicol. 2010;33:88–96.
111. Tao Z, Zhou Y, Lu J, Duan W, Qin Y, He X, et al. Caspase-8 preferentially senses the apoptosis-inducing action of NG-18, a gambogic acid derivative, in human leukemia HL-60 cells. Cancer Biol Ther. 2007;6:691–6.
112. Xie H, Qin Y, Zhou Y, Tong L, Lin L, Geng M, et al. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin. 2009;30:346–54.
113. Chen T, Zhang R-H, He S-C, Q-Y X, Ma L, Wang G-C, et al. Synthesis and antiangiogenic activity of novel gambogic acid derivatives. Molecules. 2012;17:6249–68.
114. He L, Ling Y, Fu L, Yin D, Wang X, Zhang Y. Synthesis and biological evaluation of novel derivatives of gambogic acid as anti-hepatocellular carcinoma agents. Bioorg Med Chem Lett. 2012;22:289–92.
115. Guo X-K, Sun H-P, Shen S, Sun Y, Xie F-L, Tao L, et al. Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III. Chem Biodivers. 2013;10:73–85.